Thermo Fisher Nears $10 Billion Acquisition of Clario: Reuters Report

Thermo Fisher Scientific is reportedly close to finalizing an all-cash acquisition of Clario, a clinical trial data management firm, for approximately $10 billion, according to a Financial Times report. Reuters indicated that it could not independently confirm the report. An official announcement of the potential acquisition could occur as early as Wednesday, contingent upon the absence of unforeseen complications. The acquisition, if completed, would represent Thermo Fisher's most significant deal since its $17.4 billion acquisition of PPD in 2021. Clario, formed in 2021 through the merger of ERT and Bioclinica, provides specialized software solutions for pharmaceutical manufacturers. Its current shareholders include private equity firms Nordic Capital and Astorg. This potential acquisition is consistent with Thermo Fisher's strategic objective of expanding its product and service offerings within the healthcare and pharmaceutical research industries.